SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
178.25
-0.44 (0.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close177.38
Open178.69
Bid0.00 x 1000
Ask0.00 x 1100
Day's Range178.05 - 178.90
52 Week Range123.73 - 181.41
Volume407,622
Avg. Volume772,196
Market Cap53.153B
Beta1.30
PE Ratio (TTM)11.26
EPS (TTM)15.82
Earnings DateN/A
Forward Dividend & Yield1.06 (0.60%)
Ex-Dividend Date2018-09-06
1y Target Est201.82
Trade prices are not sourced from all markets
  • GlobeNewswire1 hour ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR.

  • Japan Is Asia’s M&A King While China Gets the Pushback
    Bloombergyesterday

    Japan Is Asia’s M&A King While China Gets the Pushback

    Is it just China that faces roadblocks from the West when acquiring overseas assets, or are other foreign buyers equal targets? For the first time in three years, Japanese companies have pulled ahead of their mainland rivals, offering nearly double the $80 billion Chinese firms have shelled out for deals abroad so far this year. That makes Japan, not China, Asia’s M&A king. The Committee on Foreign Investment in the U.S. has hardened its stance toward foreign buying, no matter how small or passive, for companies that work in critical technology, infrastructure and the catch-all net of personal data — all with an eye to protecting U.S. national-security interests.

  • GlobeNewswire2 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Takeda Shareholder `Skeptical' About Shire Takeover, Sunday Times Says
    Bloomberg3 days ago

    Takeda Shareholder `Skeptical' About Shire Takeover, Sunday Times Says

    One of the top 10 shareholders in Japanese drugmaker Takeda Pharmaceutical Co. is “skeptical” on the value that will be created from the group’s $62 billion takeover of rare disease specialist Shire Plc, the Sunday Times reported, citing the unidentified investor. The deal, the biggest in Osaka-based Takeda’s history, has already faced opposition from a group of investors that calls itself “Thinking About Takeda’s Future.” It comprises former Takeda employees and shareholders who together own about 1 percent of the company’s stock and who oppose Takeda’s expansion. The Sunday Times reported the shareholder said the deal had come as a “surprise” and raised concerns about the ability of Takeda to cut costs and improve shareholder returns.

  • 4 Stocks John Paulson and Paul Tudor Jones Agree On
    GuruFocus.com5 days ago

    4 Stocks John Paulson and Paul Tudor Jones Agree On

    Gurus see value in 2 pharmaceutical companies, a chipmaker and an asset manager

  • Is Shire (SHPG) a Suitable Stock for Value Investors Now?
    Zacks5 days ago

    Is Shire (SHPG) a Suitable Stock for Value Investors Now?

    Let's see if Shire plc (SHPG) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

  • Benzinga5 days ago

    The Daily Biotech Pulse: Exelixis Liver Cancer Drug On Track For European Approval, Medtronic Goes Shopping, Opiant Snags BARDA Funding

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 20.) Abbott Laboratories (NYSE: ABT ) Acceleron ...

  • GlobeNewswire5 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire5 days ago

    Shire Receives Approval of FIRAZYR® (icatibant injection) for the Treatment of Hereditary Angioedema (HAE) Attacks in Japan

    September 21, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) the leading global biotechnology company focused on rare diseases, today announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has granted manufacturing and marketing authorisation for FIRAZYR® (icatibant injection), for the acute treatment of hereditary angioedema (HAE) attacks in adult patients with HAE.

  • GlobeNewswire6 days ago

    Health Canada has authorized TAKHZYRO(TM) (lanadelumab injection), a first-of-its-kind monoclonal antibody treatment for the prevention of hereditary angioedema (HAE) attacks

    September 20, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) and Shire Pharma Canada ULC (Shire Canada), the leading global biotechnology company focused on rare diseases, announced today that following priority review, Health Canada has authorized TAKHZYRO (lanadelumab injection) for routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults (12 years of age and older). HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of edema (swelling) in various parts of the body. "The burden HAE patients and their families face every day can’t be ignored,” said Jacquie Badiou, President, HAE Canada. “Our National Report Card shows that the unpredictable nature of this life-threatening disorder, not knowing when the next attack will come, has a negative impact on their lives and the lives of their loved ones.

  • GlobeNewswire6 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire7 days ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire8 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Company News For Sep 17, 2018
    Zacks9 days ago

    Company News For Sep 17, 2018

    Companies In The News are: ADBE,LB,NI,SHPG

  • GlobeNewswire9 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuters12 days ago

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • Takeda gets China's approval for $62 billion Shire purchase
    Reuters12 days ago

    Takeda gets China's approval for $62 billion Shire purchase

    The acquisition, which will be the largest overseas purchase by a Japanese company, has already received unconditional clearance from U.S. and Brazilian regulators and awaits approval from Japan and the European Union. Takeda expects the deal to close in the first half of 2019. Takeda's stock is down 15 percent since the company first said it was considering a bid for Shire, with investors concerned about the heavy debt burden the deal will impose on the drugmaker.

  • GlobeNewswire12 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg
    Reuters13 days ago

    Takeda weighs sale of Shire's eye care business to cut debt: Bloomberg

    Japan's Takeda Pharmaceutical is considering selling Shire Plc's eye care business once it closes its $62 billion purchase of the London-listed drugmaker, as it looks to cut the debt raised to fund the ...

  • Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg
    Reuters13 days ago

    Takeda weighs sale of Shire's eye care business to cut debt - Bloomberg

    (Reuters) - Japan's Takeda Pharmaceutical is considering selling Shire Plc's (SHP.L) eye care business once it closes its $62 billion (47 billion pounds) purchase of the London-listed drugmaker, as it ...

  • GlobeNewswire13 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt
    Bloomberg13 days ago

    Takeda Is Said to Weigh Sale of Shire Eye Drug to Cut Debt

    Takeda Pharmaceutical Co. is weighing the sale of a Shire Plc eye care business once its $62 billion purchase of the U.K.-listed biotech firm is completed, as it seeks ways to cut the debt raised to fund the deal, people familiar with the matter said. The Xiidra drug, used to treat dry eye disease, is among potential divestments being assessed by Takeda, according to the people, who asked not to be identified because the matter is private. Takeda has also been discussing with banks about a possible sale of Shire’s Natpara medicine, used to control low blood calcium levels related to decreased parathyroid hormone, the people said.

  • Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected
    Reuters14 days ago

    Takeda to pack up Illinois HQ, nearly 1,000 workers to be affected

    The Deerfield site employs just under 1,000 people — about a fifth of its U.S. employees — and a number of them will be provided with job offers and/or relocation opportunities, a Takeda spokeswoman told Reuters on Wednesday. "This move, while difficult, will allow closer collaboration across Takeda to best position our future pipeline for success. In May, Takeda agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion), a deal that will make the firm closer to becoming a top 10 global drugmaker.

  • GlobeNewswire14 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire14 days ago

    Shire Granted EU Marketing Authorization for Veyvondi® for Adults With Von Willebrand Disease

    September 12, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) the global biotech leader in rare diseases, announced today that the European Commission (EC) has granted Marketing Authorization for VEYVONDI [vonicog alfa, recombinant von Willebrand factor] (rVWF), for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease (VWD) when desmopressin (DDAVP) treatment alone is ineffective or not indicated.